These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932 [TBL] [Abstract][Full Text] [Related]
10. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Koivunen J; Verkkoniemi A; Aalto S; Paetau A; Ahonen JP; Viitanen M; Någren K; Rokka J; Haaparanta M; Kalimo H; Rinne JO Brain; 2008 Jul; 131(Pt 7):1845-53. PubMed ID: 18583368 [TBL] [Abstract][Full Text] [Related]
11. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469 [TBL] [Abstract][Full Text] [Related]
12. Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease. Ishibashi K; Ishiwata K; Toyohara J; Murayama S; Ishii K Eur J Neurosci; 2014 Aug; 40(4):2701-6. PubMed ID: 24888235 [TBL] [Abstract][Full Text] [Related]
13. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Gordon BA; Blazey TM; Su Y; Hari-Raj A; Dincer A; Flores S; Christensen J; McDade E; Wang G; Xiong C; Cairns NJ; Hassenstab J; Marcus DS; Fagan AM; Jack CR; Hornbeck RC; Paumier KL; Ances BM; Berman SB; Brickman AM; Cash DM; Chhatwal JP; Correia S; Förster S; Fox NC; Graff-Radford NR; la Fougère C; Levin J; Masters CL; Rossor MN; Salloway S; Saykin AJ; Schofield PR; Thompson PM; Weiner MM; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS Lancet Neurol; 2018 Mar; 17(3):241-250. PubMed ID: 29397305 [TBL] [Abstract][Full Text] [Related]
14. Imaging beta-amyloid burden in aging and dementia. Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554 [TBL] [Abstract][Full Text] [Related]
15. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Remes AM; Laru L; Tuominen H; Aalto S; Kemppainen N; Mononen H; Någren K; Parkkola R; Rinne JO Arch Neurol; 2008 Apr; 65(4):540-4. PubMed ID: 18413480 [TBL] [Abstract][Full Text] [Related]
16. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease. Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539 [TBL] [Abstract][Full Text] [Related]
17. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490 [TBL] [Abstract][Full Text] [Related]
18. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ; Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172 [TBL] [Abstract][Full Text] [Related]
19. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition. Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509 [TBL] [Abstract][Full Text] [Related]
20. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. Lanoiselée HM; Nicolas G; Wallon D; Rovelet-Lecrux A; Lacour M; Rousseau S; Richard AC; Pasquier F; Rollin-Sillaire A; Martinaud O; Quillard-Muraine M; de la Sayette V; Boutoleau-Bretonniere C; Etcharry-Bouyx F; Chauviré V; Sarazin M; le Ber I; Epelbaum S; Jonveaux T; Rouaud O; Ceccaldi M; Félician O; Godefroy O; Formaglio M; Croisile B; Auriacombe S; Chamard L; Vincent JL; Sauvée M; Marelli-Tosi C; Gabelle A; Ozsancak C; Pariente J; Paquet C; Hannequin D; Campion D; PLoS Med; 2017 Mar; 14(3):e1002270. PubMed ID: 28350801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]